Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received an average rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $5.8333.

Several research firms have weighed in on ZNTL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company. Guggenheim lifted their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st.

Zentalis Pharmaceuticals Trading Down 5.4%

ZNTL opened at $3.66 on Tuesday. Zentalis Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $6.95. The company has a market cap of $260.56 million, a P/E ratio of -2.12 and a beta of 1.96. The company has a fifty day moving average price of $3.88 and a two-hundred day moving average price of $2.76.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, research analysts forecast that Zentalis Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sivia Capital Partners LLC bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $27,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth about $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth about $37,000. Voleon Capital Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth about $41,000. Finally, SG Americas Securities LLC increased its position in shares of Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after acquiring an additional 8,236 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.